INBX
Price:
$14.08
Market Cap:
$203.82M
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothe...[Read more]
Industry
Biotechnology
IPO Date
2024-06-04
Stock Exchange
NASDAQ
Ticker
INBX
According to Inhibrx Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 9.32M. This represents a change of -99.04% compared to the average of 967.05M of the last 4 quarters.
The mean historical Enterprise Value of Inhibrx Biosciences, Inc. over the last ten years is 959.84M. The current 9.32M Enterprise Value has changed -2.86% with respect to the historical average. Over the past ten years (40 quarters), INBX's Enterprise Value was at its highest in in the December 2023 quarter at 1.99B. The Enterprise Value was at its lowest in in the June 2024 quarter at -25790079.04.
Average
959.84M
Median
768.66M
Minimum
565.99M
Maximum
1.72B
Discovering the peaks and valleys of Inhibrx Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 115.61%
Maximum Annual Enterprise Value = 1.72B
Minimum Annual Increase = -42.69%
Minimum Annual Enterprise Value = 565.99M
Year | Enterprise Value | Change |
---|---|---|
2023 | 1.72B | 88.02% |
2022 | 916.47M | -42.69% |
2021 | 1.60B | 115.61% |
2020 | 741.65M | -5.44% |
2019 | 784.31M | 38.57% |
2018 | 565.99M | -4.89% |
2017 | 595.11M | -20.97% |
The current Enterprise Value of Inhibrx Biosciences, Inc. (INBX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
1.41B
5-year avg
1.15B
10-year avg
959.84M
Inhibrx Biosciences, Inc.’s Enterprise Value is less than Crinetics Pharmaceuticals, Inc. (4.93B), less than Merus N.V. (2.68B), less than Lyell Immunopharma, Inc. (216.40M), greater than Kronos Bio, Inc. (5.32M), less than Opthea Limited (514.42M), less than Mineralys Therapeutics, Inc. (523.81M), less than Eliem Therapeutics, Inc. (119.64M), less than Anebulo Pharmaceuticals, Inc. (36.46M), greater than Merrimack Pharmaceuticals, Inc. (-10189682.00), less than Celcuity Inc. (574.33M), less than Enliven Therapeutics, Inc. (1.10B), less than Monte Rosa Therapeutics, Inc. (439.72M), less than Design Therapeutics, Inc. (290.40M), greater than Werewolf Therapeutics, Inc. (-1378920.00), less than Ikena Oncology, Inc. (45.73M), less than Stoke Therapeutics, Inc. (457.69M), less than Protagonist Therapeutics, Inc. (2.65B), less than DICE Therapeutics, Inc. (1.82B), less than Larimar Therapeutics, Inc. (363.34M), less than Viridian Therapeutics, Inc. (1.42B),
Company | Enterprise Value | Market cap |
---|---|---|
4.93B | $5.20B | |
2.68B | $3.11B | |
216.40M | $265.26M | |
5.32M | $54.49M | |
514.42M | $486.27M | |
523.81M | $621.09M | |
119.64M | $342.68M | |
36.46M | $37.86M | |
-10189682.00 | $223.97M | |
574.33M | $489.74M | |
1.10B | $1.20B | |
439.72M | $521.60M | |
290.40M | $318.21M | |
-1378920.00 | $84.67M | |
45.73M | $82.52M | |
457.69M | $605.41M | |
2.65B | $2.77B | |
1.82B | $2.27B | |
363.34M | $393.05M | |
1.42B | $1.60B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Inhibrx Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Inhibrx Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Inhibrx Biosciences, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Inhibrx Biosciences, Inc. (INBX)?
What is the 3-year average Enterprise Value for Inhibrx Biosciences, Inc. (INBX)?
What is the 5-year average Enterprise Value for Inhibrx Biosciences, Inc. (INBX)?
How does the current Enterprise Value for Inhibrx Biosciences, Inc. (INBX) compare to its historical average?